

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JFCW

In re Applicant:

Irit SAGI et al

Serial No.: 10/551,715

Filed: October 3, 2005

For: Antibodies And Pharmaceutical Compositions
Containing Same Useful For Inhibiting Activity Of
Metalloproteins

Examiner: Not Yet Assigned

Group Art Unit: 1644

Attorney
Docket: 29993

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,



Martin D. Moynihan
Registration No. 40,338

Dated: June 3, 2007

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1669A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

APPENDIX

Trademark Office: U.S. DEPARTMENT OF COMMERCE

A circular stamp with a double-line border. At the top, the word "SEARCHED" is printed in a bold, sans-serif font. In the center, the date "JUN 06 2007" is printed. At the bottom, the text "PATENT & TRADEMARK OFFICE" is printed in a curved, bold, sans-serif font.

Sheet

1

1

40

Case Number: 10-00000

20002

U.S. PATENT DOCUMENTS

/Mohammad Meah/

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code ² Number ³ Kind Code ³ (if known)				
/Mohammed Meah	1	EP 0737984	02-12-1997	Sakaki et al.		
/MM	2	EP 0780386	06-25-1997	Bender et al.		
	3	PCT WO 90/05719	05-31-1990	Campion et al.		
	4	PCT WO 93/20047	10-14-1993	Crimmin et al.		
	5	PCT WO 95/09841	04-13-1995	Crimmin et al.		
	6	PCT WO 95/29689	09-9-1995	Durette et al.		
	7	PCT WO 95/29892	09-9-1995	DeCicco et al.		
	8	PCT WO 96/06074	02-29-1996	Beckett et al.		
	9	PCT WO 97/24117	07-10-1997	Groneberg et al.		
	10	PCT WO 97/49679	12-31-1997	Takahashi et al.		
/MM						
Examiner Signature	/Mohammad Meah/				Date Considered	02/23/2008


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See *Codes of USPTO Patent Documents* at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

* Japanese patent documents at www.uspto.gov or WIPO ST.16. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.16).

* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.67 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /MM/



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/551,715
Filing Date	October 3, 2005
First Named Inventor	Irit SAGI et al
Group Art Unit	1644
Examiner Name	Not yet Assigned

Sheet	2	Of	8	Attorney Docket Number	29993
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/MM/	11	Mohler et al. "Protection Against A Lethal Dose of Endotoxin by An Inhibitor of Tumour Necrosis Factor Processing", <i>Nature</i> , 370: 218-220, 1994.			
	12	Momenteau et al. "Both-Faces Hindered Porphyrins. Part I. Synthesis and Characterization of Basket-Handle Porphyrins and Their Iron Complexes", <i>Journal of Chemical Society Perkin Transactions</i> , 1: 189-196, 1983.			
	13	Collman et al. "Effect of Axial Base on Dioxygen and Carbon Monoxide Affinities of Iron(II) Porphyrins. Imidazole Vs. Pyridine", <i>Inorganic Chemistry</i> , 22: 1427-1432, 1983.			
	14	Collman et al. "Reversible Oxygen Adduct Formation in Ferrous Complexes Derived From A 'Picket Fence' Porphyrin. A Model for Oxymyoglobin", <i>Journal of the American Chemical Society</i> , 95(23): 7868-7870, 1973.			
	15	Collman et al. "Picket Fence Porphyrins". Synthetic Models for Oxygen Binding Hemoproteins", <i>Journal of the American Chemical Society</i> , 97(6): 1427-1439, 1975.			
	16	Cote et al. "Generation of Human Monoclonal Antibodies Reactive With Cellular Antigens", <i>Proc. Natl. Acad. Sci. USA</i> , 80(7)[Part I: Biological Sciences]: 2026-2030, 1983.			
	17	Baldwin et al. "Synthesis of Iron(II) 'C2-Capped Strapped' + Porphyrin Complexes and Their Reaction With Dioxygen", <i>Journal of the Chemical Society, Dalton Transactions</i> , P-1739-1746, 1984.			
	18	Davidson et al. "The Inhibition of Matrix Metalloproteinase Enzymes", <i>Chemistry and Industry</i> , &: 258-261, 1997.			
	19	De Kruif et al. "Selection and Application of Human Single Chain Fv Antibody Fragments From A Semi-Synthetic Phage Display Library With Designed CDR3 Regions", <i>Journal of Molecular Biology</i> , 248: 97-105, 1995.			
	20	Dean et al. "Evidence for Metalloproteinase and Metalloproteinase Inhibitor Imbalance in Human Osteoarthritis Cartilage", <i>Journal of Clinical Investigation</i> , 84: 678-685, 1989.			
	21	Denis et al. "Matrix Metalloproteinase Inhibitors: Present Achievements and Future Prospects", <i>Investigational New Drugs</i> , 15: 175-185, 1997.			
	22	De Filippis et al. "Structural Studies on the Zinc-Endopeptidase Light Chain of Tetanus Neurotoxin", <i>European Journal of Biochemistry</i> , 229: 61-69, 1995.			
	23	Deshpande et al. "A Study of Zinc-Dependent Metalloendopeptidase Inhibitors as Pharmacological Antagonists in Botulinum Neurotoxin Poisoning", <i>Toxicology</i> , 33(4): 551-557, 1995.			
↓	24	Diekmann et al. "Cyclophane Porphyrin", <i>Journal of the American Chemical Society</i> , 93(16): 4068-4070, 1971.			
/MM/	25	Docherty et al. "The Matrix Metalloproteinases and Their Natural Inhibitors: Prospects for Treating Degenerative Tissue Diseases", <i>Tibtech</i> , 10: 201-207, 1992.			

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file to or by the USPTO to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/551,715
Filing Date	October 3, 2005
First Named Inventor	Irit SAGI et al
Group Art Unit	1644
Examiner Name	Not yet Assigned



Sheet	3	Of 8	Attorney Docket Number
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/MM/	26	Edlund et al. "Cell-Specific Expression of the Rat Insulin Gene: Evidence for Role of Two Distinct 5 ⁸ (Prime) Flanking Elements", <i>Science</i> , 230(4728): 912-916, 1985.	
	27	Fingl et al. "Introduction. General Principles", <i>The Pharmacological Basis of Therapeutics</i> , Sec. I(Chap.1): 1-46, 1975.	
	28	Fishwild et al. "High-Avidity Human IgG1 Monoclonal Antibodies From A Novel Strain of Minilocus Transgenic Mice", <i>Nature Biotechnology</i> , 14: 845-851, 1996.	
	29	Freije et al. "Molecular Cloning and Expression of Collagenase-3, A Novel Human Matrix Metalloproteinase Produced by Breast Carcinomas", <i>The Journal of Biological Chemistry</i> , 269(24): 16766-16773, 1994.	
	30	Fridman et al. "Domain Structure of Human 72-KDa Gelatinase/Typ IV Collagenase", <i>The Journal of Biological Chemistry</i> , 267(22): 15398-15405, 1992.	
	31	Gálvez et al. "Membrane Type 1-Matrix Metalloproteinase Is Activated During Migration of Human Endothelial Cells and Modulates Endothelial Motility and Matrix Remodeling", <i>The Journal of Biological Chemistry</i> , 276(40): 37491-37500, 2001.	
	32	Gearing et al. "Processing of Tumour Necrosis Factor- α Precursor by Metalloproteinases", <i>Nature</i> , 370: 555-557, 1994.	
	33	Gogly et al. "Collagen Zymography As A Sensitive and Specific Technique for the Determination of Subpicogram Levels of Interstitial Collagenase", <i>Analytical Biochemistry</i> , 255: 211-216, 1998.	
	34	Gomez et al. "Tissue Inhibitors of Metalloproteinases: Structure, Regulation and Biological Functions", <i>European Journal of Cell Biology</i> , 74: 111-122, 1997.	
	35	Gordon et al. "Metalloproteinase Inhibitors as Therapeutics", <i>Clinical and Experimental Rheumatology</i> , 11(Suppl.8): S91-S94, 1993.	
	36	Grams et al. "Structure Determination and Analysis of Human Neutrophil Collagenase Complexed With A Hydroxamate Inhibitor", <i>Biochemistry</i> , 34: 14012-14020, 1995.	
	37	Hammond et al. "Angiogenic Gene Therapy for Heart Disease: A Review of Animal Studies and Clinical Trials", <i>Cardiovascular Research</i> , 49: 561-567, 2001.	
	38	Harada et al. "Control of Photoinduced Electron Transfer From Zinc-Porphyrin to Methyl Viologen by Supramolecular Formation Between Monoclonal Antibody and Zinc-Porphyrin", <i>Photochemistry and Photobiology</i> , 70(3): 298-302, 1999.	
	39	Heath et al. "Phase I Trial of the matrix Metalloproteinase Inhibitor BAY12-9566 in Patients With Advanced Solid Tumors", <i>Cancer Chemotherapy and Pharmacology</i> , 48: 269-274, 2001.	
	40	Henriet et al. "Tissue Inhibitors of Metalloproteinases (TIMP) in Invasion and Proliferation", <i>APMIS</i> , 107: 111-119, 1999.	
/MM/	41	High "Gene Therapy: A 2001 Perspective", <i>Haemophilia</i> , 7(Suppl.1): 23-27, 2001.	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/551,715
Filing Date	October 3, 2005
First Named Inventor	Irit SAGI et al
Group Art Unit	1644
Examiner Name	Not yet Assigned



Sheet	4	OF	8	Attorney Docket Number	29993
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials /MM/	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, (pages), volume-issue number(s), publisher, city and/or country where published			T ²
	42	Hill et al. "Inhibition of Bone Resorption In Vitro by Selective Inhibitors of Gelatinase and Collagenase", Biochemical Journal, 308: 167-175, 1995.			
	43	Hodgson "Remodeling MMPs. Matrix Metalloproteinase Inhibitors Will Be Approved as Drugs, Probably This Year, But Questions Remain Concerning Their Specificity, Bioavailability, and Potential Long-Term Toxicity", Bio/Technology, 13: 554-557, 1995.			
	44	Huston et al. "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in An Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia Coli", Proc. Natl. Acad. Sci. USA, 85(16): 5879-5883, 1988.			
	45	Inbar et al. "Localization of Antibody-Combining Sites Within the Variable Portions of Heavy and Light Chains", Proc. Natl. Acad. Sci. USA, 69(9): 2659-2662, 1972.			
	46	Isner "Myocardial Gene Therapy", Nature, 415: 234-239, 2002.			
	47	Jones et al. "Replacing the Complementarity-Determining Regions in A Human Antibody With Those From A Mouse", Nature, 321: 522-525, 1986.			
	48	Kleifeld et al. "X-Ray Absorption Studies of Human Matrix Metalloproteinase-2 (MMP-2) Bound to A Highly Selective Mechanism-Based Inhibitor. Comparison With the Latent and Active Forms of the Enzyme", The Journal of Biological Chemistry, 276(20): 17125-17131, 2001.			
	49	Knight et al. "A Novel Coumarin-Labelled Peptide for Sensitive Continuous Assays of the Matrix Metalloproteinases", FEBS Letters, 296(3): 263-266, 1992.			
	50	Köhler et al. "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", Nature, 256: 495-497, 1975.			
	51	Korkhin et al. "NADP-Dependent Bacterial Alcohol Dehydrogenases: Crystal Structure, Cofactor-Binding and Cofactor Specificity of the ADHs of Clostridium Beijerinckii and Thermoanaerobacter Brockii", Journal of Molecular Biology, 278: 967-981, 1998.			
	52	Kozbor et al. "Specific Immunoglobulin Production and Enhanced Tumorigenicity Following Ascites Growth of Human Hybridomas", Journal of Immunological Methods, 81: 31-42, 1985.			
	53	Larrick et al. "PCR Amplification of Antibody Genes", Methods: A Companion to Methods in Enzymology, 2(2): 106-110, 1991.			
	54	Lonberg et al. "Human Autoantibodies From Transgenic Mice", International Reviews of Immunology, 13: 65-93, 1995.			
↓	55	Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications", Nature, 368: 856-859, 1994.			
/MM/	56	Maret et al. "The PH Variation of Steady-State Kinetic Parameters of Site-Specific Co2+-Reconstituted Liver Alcohol Dehydrogenase", The Journal of Biological Chemistry, 266(31): 20636-20644, 1991.			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/551,715
Filing Date	October 3, 2005
First Named Inventor	Irit SAGI et al
Group Art Unit	1644
Examiner Name	Not yet Assigned



Sheet	5	OF	8	Attorney Docket Number	29993
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials /MM/	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	57	Marks et al. "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", <i>Bio/Technology</i> , 10: 779-783, 1992.			
	58	McGeehan et al. "Regulation of Tumour Necrosis Factor- α Processing by A Metalloproteinase Inhibitor", <i>Nature</i> , 370: 558-561, 1994.			
	59	Momentau et al. "Basket Handle" Porphyrins: New Synthetic Iron (II) Complexes for Oxygen Binding", <i>Journal of Molecular Catalysis</i> , 7: 315-320, 1980.			
	60	Momentau et al. "Basket Handle" Porphyrins and Their Ferrous Complexes as Stable Oxygen Carriers", <i>Nouveau Journal de Chimie</i> , 3(2): 77-79, 1979.			
	61	Morgunova et al. "Structure of Human Pro-Matrix Metalloproteinase-2: Activation Mechanism Revealed", <i>Science</i> , 284(5420): 1667-1670, 1999.			
	62	Nagase et al. "Matrix Metalloproteinases", <i>The Journal of Biological Chemistry</i> , 274(31): 21491-21494, 1999.			
	63	Morrison "Success in Specification", <i>Nature</i> , 368: 812-813, 1994.			
	64	Nakada et al. "Expression and Tissue Localization of Membrane-Type 1, 2, and 3 Matrix Metalloproteinases in Human Astrocytic Tumors", <i>American Journal of Pathology</i> , 154(2): 417-428, 1999.			
	65	Netzel-Arnett et al. "Continuously Recording Fluorescent Assays Optimized for Five Human Matrix Metalloproteinases", <i>Analytical Biochemistry</i> , 195: 86-92, 1991.			
	66	Neuberger "Generating High-Avidity Human Mabs in Mice", <i>Nature Biotechnology</i> , 14: 826, 1996.			
	67	Newby et al. "Extracellular Matrix Degrading Metalloproteinases in the Pathogenesis of Arteriosclerosis", <i>Basic Research in Cardiology</i> , 89(Suppl. 1): 59-70, 1994.			
	68	O'Connor et al. "Matrix Metalloproteinases and Lung Disease", <i>Thorax</i> , 49: 602-609, 1994.			
	69	Orlandi et al. "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction", <i>Proc. Natl. Acad. Sci. USA</i> , 86(10): 3833-3837, 1989.			
	70	Pack et al. "Improved Bivalent Miniantibodies, With Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of Escherichia Coli", <i>Bio/Technology</i> , 11: 1271-1277, 1993.			
	71	Payne "Metallo- β -Lactamases - A New Therapeutic Challenge", <i>Journal of Medical Microbiology</i> , 39: 93-99, 1993.			
	72	Pinkert et al. "An Albumin Enhancer Located 10 Kb Upstream Functions Along With Its Promoter to Direct Efficient, Liver-Specific Expression in Transgenic Mice", <i>Genes & Development</i> , 1: 268-276, 1987.			
↓	73	Porter "The Hydrolysis of Rabbit γ -Globulin and Antibodies With Crystalline Papain", <i>Biochemical Journal</i> , 73: 119-126, 1992.			
/MM/	74	Presta "Antibody Engineering", <i>Current Opinion in Structural Biology</i> , 2: 593-596, 1992.			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/551,715
Filing Date	October 3, 2005
First Named Inventor	Irit SAGI et al
Group Art Unit	1644
Examiner Name	Not yet Assigned



Sheet	6	Of	8	Attorney Docket Number	29993
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/MM/	75	Rasmussen et al. "Matrix Metalloproteinase Inhibition as A Novel Anticancer Strategy: A Review With Special Focus on Batinostat and Marimastat", Pharmacology & Therapy, 75(1): 69-75, 1997.			
	76	Ray et al. "The Role of Matrix Metalloproteases and Their Inhibitors in Tumour Invasion, Metastasis and Angiogenesis", European Respiratory Journal, 7: 2062-2072, 1994.			
	77	Rehr et al. "Theoretical X-Ray Absorption Fine Structure Standards", Journal of American Chemical Society, 113(14): 5135-5140, 1991.			
	78	Reponen et al. "Molecular Cloning of Murine 72-Kda Type IV Collagenase and Its Expression During Mouse Development", The Journal of Biological Chemistry, 267(11): 7856-7862, 1992.			
	79	Riechmann et al. "Reshaping Human Antibodies for Therapy", Nature, 332: 323-327, 1988.			
	80	Ross et al. "Chelometric Indicator Titrations With the Solid-State Cupric Ion-Selective Electrode", Analytical Chemistry, 41(13): 1900-1902, 1969.			
	81	Sato et al. "A Matrix Metalloproteinase Expressed on the Surface of Invasive Tumour Cells", Nature, 370: 61-65, 1997.			
	82	Schwartz et al. "Synthetic Inhibitors of Bacterial and Mammalian Interstitial Collagenases", Progress in Medicinal Chemistry, 29(Chap.8): 271-334, 1992.			
	83	Shapiro et al. "Cloning and Characterization of A Unique Elastolytic Metalloproteinase Produced by Human Alveolar Macrophages", The Journal of Biological Chemistry, 268(32): 23824-23829, 1993.			
	84	Singh et al. "Relationship Between Structure and Bioavailability in A Series of Hydroxamate Based Metalloprotease Inhibitors", Bioorganic & Medicinal Chemistry Letters, 5(4): 337-342, 1995.			
	85	Sombia et al. "Gene Therapy: Trials and Tribulations", Nature Reviews/Genetics, 1: 91-99, 2000.			
	86	Stern et al. "The UWXAFS Analysis Package: Philosophy and Details", Physica B, 208 & 209: 117-120, 1995.			
	87	Tonkinson et al. "Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents", Cancer Investigation, 14(1): 54-65, 1996.			
	88	Traylor et al. "Anthracene Heme Cyclophanes. Steric Effects in CO, O ₂ , and RNC Binding", Journal of the American Chemical Society, 107: 604-614, 1985.			
	89	Uemori et al. "O ₂ and CO Binding to 'Jellyfish' Type Iron(II) Porphyrins", Inorganic Chemistry, 28: 1690-1694, 1989.			
/MM/	90	Van Wart et al. "The Cysteine Switch: A Principle of Regulation of Metalloproteinase Activity With Potential Applicability to the Entire Matrix Metalloproteinase Gene Family", Proc. Natl. Acad. Sci. USA, 87(14): 5578-5582, 1990.			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant or Inventor's client identification number (if applicable). * Applicant or Inventor place a check mark here if English language Translation is attached.

This column of information is required by 37 CFR 1.87 and 1.88. The information is required to obtain or retain a benefit by the individual which is to be (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/551,715
Filing Date	October 3, 2005
First Named Inventor	Irit SAGI et al
Group Art Unit	1644
Examiner Name	Not yet Assigned



Sheet	7	Of	8	Attorney Docket Number	29993
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/MM/	91	Verhoeven et al. "Reshaping Human Antibodies: Grafting An Antilysozyme Activity", <i>Science</i> , 239(4847): 1534-1536, 1998.			
	92	Walakovits et al. "Detection of Stromelysin and Collagenase in Synovial Fluid From Patients With Rheumatoid Arthritis and Posttraumatic Knee Injury", <i>Arthritis and Rheumatism</i> , 35(1): 35-42, 1992.			
	93	Weingarten et al. "Cleavage Site Specificity of Vertebrate Collagenases", <i>Biochemical and Biophysical Research Communications</i> , 139(3): 1184-1187, 1986.			
	94	Whitlow et al. "Single-Chain Fv Proteins and Their Fusion Proteins", <i>Methods: A Companion to Methods in Enzymology</i> , 2(2): 97-105, 1991.			
	95	Will et al. "The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation", <i>The Journal of Biological Chemistry</i> , 271(29): 17119-17123, 1996.			
	96	Winoto et al. "A Novel, Inducible and T Cell-Specific Enhancer Located at the 3' End of the T Cell Receptor α Locus", <i>The EMBO Journal</i> , 8(3): 729-733, 1989.			
	97	Winter et al. "Man-Made Antibodies", <i>Nature</i> , 349: 293-299, 1991.			
	98	Zabinsky et al. "Multiple-Scattering Calculations of X-Ray-Absorption Spectra", <i>Physical Review B</i> , 52(4): 2995-3009, 1995.			
	99	Zucker et al. "Critical Appraisal of the Use of Matrix Metalloproteinase Inhibitors in Cancer Treatment", <i>Oncogene</i> , 19: 6642-6650, 2000.			
	100	Crowe et al. "A Metalloproteinase Inhibitor Blocks Shedding of the 80-KD TNF Receptor and TNF Processing in T Lymphocytes", <i>Journal of Experimental Medicine</i> , 181: 1205-1210, 1995.			
	101	Almog et al. "Condensation of Tetraldehydes With Pyrrole. Direct Synthesis of 'Capped' Porphyrins", <i>Journal of the American Chemical Society</i> , 97(1): 226-227, 1975.			
	102	Almog et al. "Synthesis of 'Capped' Porphyrins", <i>Tetrahedron</i> , 37(21): 3589-3601, 1981.			
	103	Armstrong et al. "Structural Remodelling in Heart Failure: Gelatinase Induction", <i>Canadian Journal of Cardiology</i> , 10(2): 214-220, 1994.			
	104	Axisa et al. "Prospective, Randomized, Double-Blind Trial Investigating the Effect of Doxycycline on Matrix Metalloproteinase Expression Within Atherosclerotic Carotid Plaques", <i>Editorial Comment, Stroke</i> , 33: 2858-2864, 2002.			
	105	Bode et al. "Endoproteinase-Protein Inhibitor Interactions", <i>APMIS</i> , 107: 3-10, 1999.			
	106	Banerji et al. "A Lymphocyte-Specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes", <i>Cell</i> , 33: 729-740, 1983.			
/MM/	107	Battersby et al. "Synthetic Studies Related to Myoglobin: Syntheses of Bridged Porphyrin Systems", <i>Journal of the Chemical Society, Chemical Communications</i> , P.879-891, 1976.			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/551,715
Filing Date	October 3, 2005
First Named Inventor	Irit SAGI et al
Group Art Unit	1644
Examiner Name	Not yet Assigned



Sheet	8	Of	8	Attorney Docket Number	29993
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/MM/	108	Battersby et al. "Synthetic Routes to Singly and Doubly Bridged Porphyrins", Tetrahedron Letters, 34: 3169-3172, 1978.			
	109	Belaaouaj et al. "Human Macrophage Metalloelastase. Genomic Organization, Chromosomal Location, Gene Linkage, and Tissue-Specific Expression", The Journal of Biological Chemistry, 270(24): 14568-14575, 1995.			
	110	Bird et al. "Single-Chain Antigen-Binding Proteins", Science, 242(4877): 423-426, 1988.			
	111	Bode et al. "The X-Ray Crystal Structure of the Catalytic Domain of Human Neutrophil Collagenase by A Substrate Analogue Reveals the Essentials for Catalysis and Specificity", The EMBO Journal, 13(6): 1263-1269, 1994.			
	112	Bode et al. "Structural Properties of Matrix Metalloproteinases", CMLS, Cellular and Molecular Life Sciences, 55: 639-652, 1999.			
	113	Boitrel et al. "Synthesis of 'Gyroscope-Like' Porphyrins", Journal of the Chemical Society, Chemical Communications, P.1820-1821, 1985.			
	114	Borkakoti "Matrix Metalloproteinases: Variations on the Theme", Progress in Biophysics & Molecular Biology, 70: 73-94, 1998.			
	115	Brown et al. "Potent and Selective Mechanism-Based Inhibition of Gelatinases", Journal of the American Chemical Society, 122: 6799-6800, 2000.			
	116	Byrne et al. "Multiplex Gen Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989.			
	117	Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988.			
	118	Cawston et al. "A Rapid and Reproducible Assay for Collagenase Using [1-14C]Acetylated Collagen", Analytical Biochemistry, 99: 340-345, 1979.			
	119	Cawston et al. "Purification of Rabbit Bone Inhibitor of Collagenase", Biochemical Journal, 195: 159-165, 1981.			
	120	Cawston et al. "Mammalian Collagenases", Methods in Enzymology, 80(Chap.52): 711-722, 1981.			
↓	121	Cole et al. "Human Monoclonal Antibodies", Molecular and Cellular Biochemistry, 62: 109-120, 1984.			
/MM/	122	Lecas et al. "Condensation D'Acides Amines sur des Meso-Amino-2-Phenyl Porphyrines", Tetrahedron Letters, 26(8): 1019-1022, 1985.			

Signature	/Mohammad Meah/	02/23/2008
		Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MM/